Inspire Medical Systems (INSP) Earnings Date & Reports

Key Takeaways

• Inspire Medical Systems (INSP) reported third-quarter 2025 revenue of $224.5 million, up 10% from $203.2 million in the prior-year period.
• Adjusted earnings per share (EPS) came in at $0.38, far ahead of the consensus estimate for a loss of $0.19 per share.
• Diluted net income per share was $0.34, down from $0.60 a year earlier, reflecting higher operating expenses tied to patient marketing and corporate costs.
• Full-year 2025 revenue guidance was reaffirmed at $900 million to $910 million, while EPS guidance was raised to $0.90 to $1.00 from a prior range of $0.40 to $0.50.
• Gross margin improved to 85.8% from 84.1%, helped by higher sales volume and a favorable mix of the newer Inspire V system.
• For deeper insight into INSP, explore Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• You can also explore Trending AI Robots for automated, AI-driven trading ideas across the market.

Earnings Context and Why It Matters

Inspire Medical Systems is a leader in implantable neurostimulation therapy for obstructive sleep apnea (OSA), offering an alternative to traditional CPAP treatment. The third quarter carried added significance because the company was in the midst of transitioning its installed base to its next-generation Inspire V system. Investors were watching whether that product transition would disrupt revenue momentum or reinforce the company's competitive position. The quarter also unfolded against a backdrop of rising interest in GLP-1 weight-loss medications, which have fueled debate about their potential impact on the OSA patient population. With the stock trading well below its historical highs heading into the report, this earnings release served as a key test of both growth durability and management's execution.

Reported Results

Inspire Medical Systems reported third-quarter 2025 revenue of $224.5 million, a 10% increase from $203.2 million in the same period last year. U.S. revenue rose 9% to $214.4 million, while revenue outside the U.S. climbed 37% to $10.1 million. Adjusted EPS of $0.38 comfortably beat the consensus estimate of a $0.19 loss, while GAAP diluted EPS came in at $0.34, down from $0.60 a year earlier. Gross margin expanded to 85.8% from 84.1%, reflecting higher sales volume and a greater mix of the Inspire V system. Operating income declined to $9.6 million from $14.3 million, as operating expenses increased 17% year over year, driven largely by patient marketing and general corporate costs.

Management reaffirmed full-year 2025 revenue guidance of $900 million to $910 million, implying 12% to 13% growth, and raised its diluted net income per share outlook to $0.90 to $1.00, up sharply from a previous range of $0.40 to $0.50. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) was $44.0 million, roughly in line with $44.5 million a year earlier.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to refine your own search across industries and find setups that match your strategy.

Market Reaction and Investor Sentiment

Investors responded enthusiastically to the beat-and-raise quarter. Shares of Inspire Medical Systems jumped roughly 17% following the report, signaling that the market viewed the EPS outperformance and upgraded full-year earnings guidance as evidence of stabilizing profitability. The positive reaction came even as several analysts trimmed their price targets in the days after the announcement, reflecting broader valuation recalibration rather than a change in fundamental conviction. Sentiment appeared most encouraged by the company's reaffirmed revenue outlook and its progress on the Inspire V rollout, with more than 98% of physician training complete and over 75% of centers implanting the new system.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be focused on how the Inspire V transition progresses through the remainder of 2025 and into 2026. Management indicated that most centers should complete the switch by year-end, with a smaller number continuing to use the legacy Inspire IV system for economic reasons. A smooth transition is important because the newer device carries a lower cost of goods sold, which has helped support gross margin.

Another key theme is the interplay between Inspire therapy and GLP-1 medications, a class of drugs increasingly used to treat obesity and, in some cases, obstructive sleep apnea. The company's survey work suggests these drugs are bringing more patients into sleep clinics, which management sees as an opportunity to expand the pool of patients eligible for Inspire therapy over time. Monitoring patient flow and provider capacity will be central to the growth story.

Finally, investors should track operating expense discipline and upcoming Medicare reimbursement changes. Management has signaled that operating expenses should align more closely with revenue growth, while proposed increases to hospital and ambulatory surgical center reimbursement for the company's implant procedure are expected to take effect in January 2026. Combined with formal 2026 guidance expected in January, these factors will shape how the market evaluates the company's path toward sustained, profitable growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations